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Introduction: To evaluate safety and efficacy of stereotactic body 
radiotherapy (SBRT) for stage I non–small-cell lung cancer (NSCLC) 
in a patterns-of-care and patterns-of-outcome analysis.
Methods: The working group “Extracranial Stereotactic 
Radiotherapy” of the German Society for Radiation Oncology per-
formed a retrospective multicenter analysis of practice and outcome 
after SBRT for stage I NSCLC. Sixteen German and Austrian centers 
with experience in pulmonary SBRT were asked to participate.
Results: Data of 582 patients treated at 13 institutions between 1998 
and 2011 were collected; all institutions, except one, were academic 
hospitals. A time trend to more advanced radiotherapy technolo-
gies and escalated irradiation doses was observed, but patient char-
acteristics (age, performance status, pulmonary function) remained 
stable over time. Interinstitutional variability was substantial in all 
treatment characteristics but not in patient characteristics. After an 
average follow-up of 21 months, 3-year freedom from local progres-
sion (FFLP) and overall survival (OS) were 79.6% and 47.1%, respec-
tively. The biological effective dose was the most significant factor 
influencing FFLP and OS: after more than 106 Gy biological effective 
dose as planning target volume encompassing dose (N = 164), 3-year 
FFLP and OS were 92.5% and 62.2%, respectively. No evidence of a 
learning curve or improvement of results with larger SBRT experience 
and implementation of new radiotherapy technologies was observed.
Conclusion: SBRT for stage I NSCLC was safe and effective in 
this multi-institutional, academic environment, despite consider-
able interinstitutional variability and time trends in SBRT practice. 
Radiotherapy dose was identified as a major treatment factor influ-
encing local tumor control and OS.
Key Words: Stereotactic body radiotherapy, Non–small-cell lung 
cancer, Patterns-of-care.
(J Thorac Oncol. 2013;8: 1050-1058)
Stereotactic body radiotherapy (SBRT) is considered the treatment of choice for early-stage non–small-cell lung 
cancer (NSCLC) if patients are inoperable because of medi-
cal comorbidities. Several prospective phase II trials reported 
consistently high rates of local tumor control of 84% to 98%,1–
6 which is substantially better compared with historical data 
using conventional radiotherapy.7 A meta-analysis suggested 
that this improved local tumor control by SBRT transfers into 
an improved overall survival (OS).8 In addition, two pop-
ulation-based analyses reported improved OS in the elderly 
patients by the introduction of SBRT.9,10 Despite this intensi-
fied local treatment, toxicity has been reduced by the use of 
modern radiotherapy technologies, which focus the irradia-
tion to small volumes. This high accuracy of SBRT for best 
possible sparing of lung tissue is of particular importance in 
the fragile patient population frequently suffering from severe 
pulmonary comorbidities.
On the basis of these promising results, SBRT for 
early-stage NSCLC was quickly adopted in the radiotherapy 
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community: a national survey in the United States reported 
that 57% of all responding physicians practiced SBRT for 
lung cancer in 2010,11 and a similar survey in Italy reported 
SBRT practice in 41% of all responding radiotherapy centers 
in 2009.12 However, there exist concerns about this rapid and 
widespread implementation of SBRT.
Despite consistent clinical outcome, the methodol-
ogy of SBRT varied substantially, for example, all prospec-
tive trials used different fractionations and total irradiation 
doses. Furthermore, multiple novel technologies have been 
developed in the recent years, addressing various aspects of 
SBRT, although their potential impact on clinical outcome is 
unknown. This lack of standardization bears the risk of jeop-
ardizing the results achieved so far when SBRT is practiced 
outside of specialized centers or well-defined study protocols.
Another issue of concern is the limited OS of patients 
treated with SBRT for NSCLC because of the high competing 
risk of death from their comorbidities. All prospective stud-
ies and the majority of the retrospective studies only included 
small patient numbers, which makes analysis of long-term 
safety and efficacy difficult.
After Sweden and Japan pioneered work in SBRT, 
Germany and Austria started with the practice of SBRT in 1998. 
A working group, Extracranial Stereotactic Radiotherapy, was 
established in 2004 within the German Society for Radiation 
Oncology (DEGRO) for development of national guidelines, 
and coordinated education about implementation and practice 
of SBRT. In 2011, a patterns-of-care and outcome analysis 
was initiated within this working group to investigate imple-
mentation, practice, and outcome—safety and efficacy—after 
SBRT for stage I NSCLC in Germany and Austria.
MATERIALS AND METHODS
In 2011, the initiative to this analysis was started within 
the working group Extracranial Stereotactic Radiotherapy of 
the DEGRO. Inclusion criterion for participation in this analy-
sis was experience in pulmonary SBRT (primary and second-
ary tumors), with minimum 20 patients treated until 2011. All 
centers with SBRT practice documented in the working group 
Extracranial Stereotactic Radiotherapy were asked in written 
form for participation in this analysis. In addition, responding 
centers were asked about other potential centers with experi-
ence in SBRT, which were also invited.
It was the aim of this study to analyze safety (30- and 
60-day mortality; radiation-induced pneumonitis) and efficacy 
(OS and freedom from local progression [FFLP]) of SBRT, for 
stage I NSCLC. FFLP was defined as regrowth of the tumor 
in the treated area; recurrences distant to the primary lesion in 
the same lobe were not classified as local failure but as distant 
metastases. There was no central definition of local progres-
sion in terms of computed tomography (CT) morphological 
criteria, fluoro-deoxy-glucose positron emission tomography 
(FDG-PET) imaging, or biopsy confirmation.
A database in Excel format was generated consisting 
of 35 items, patient characteristics (age, sex, performance 
status, pretreatment pulmonary function), tumor character-
istics (biopsy status, histopathology, tumor stage, maximum 
tumor diameter, staging FDG-PET), treatment characteristics 
(immobilization, image guidance, single-fraction dose at 
isocenter [maximum dose in PTV]) and PTV-encompassing 
dose (minimum PTV dose), dose inhomogeneity within PTV 
(PTV-encompassing dose/maximum PTV dose), number of 
treatment fractions (dose calculation algorithm), and outcome 
characteristics (FFLP, regional recurrence, distant recurrence, 
death, radiation-induced pneumonitis).
Inclusion criteria for this analysis were clinical or his-
topathological diagnosis of stage I NSCLC; clinical diagnosis 
based on CT ± FDG-PET imaging was also allowed. SBRT 
was not defined by the number of treatment fractions (e.g., ≤5 
fractions) but by a combination of the target volume concept 
(primary tumor only without elective nodal irradiation), con-
formal treatment planning (3Dimensional conformal, inten-
sity-modulated radiation therapy, volumetric modulated arc 
therapy), and stereotactic or image-guided patient setup. The 
participating centers were asked to include in the database all 
patients treated at their institution fulfilling the criteria above. 
If in-house databases existed for this patient cohort, the com-
plete follow-up of the patients was to be provided. For centers 
without in-house databases, the latest information from clini-
cal follow-up was to be documented.
To correlate irradiation doses with clinical results, bio-
logical effective doses (BED) were calculated: an α/β-ratio of 
10 Gy was assumed for the pulmonary tumor and BED was 
calculated using the linear-quadratic model:
BED Gy = dose/fraction × fraction number (1+ fraction 
dose/α/ß)
Statistical analyses were performed with Statistica X 
(Statsoft, Tulsa, OK), and all statistical tests were two-sided. A 
p value of 0.05 or less was considered statistically significant. 
The Pearson χ2 or Fisher’s exact test and Kruskal-Wallis analy-
sis of variance were used to compare categorical and continu-
ous variables between groups, respectively. Receiver operating 
characteristics (ROC) curves were used to test prognostic fac-
tors (tumor size, irradiation dose) in predicting outcome, with 
their performances measured based on the area under the ROC 
curve. Estimated likelihood of events was calculated using the 
Kaplan–Meier method with start of follow-up on the last day 
of SBRT treatment. The log-rank test was used to compare dif-
ferences between curves in univariate analysis. Multivariate 
analysis (MVA) was performed using Cox proportional hazard 
method with backward exclusion of nonsignificant variables; 
all variables that were statistically significant in the univariate 
analysis were included in the MVA.
RESULTS
Patterns-of-Care
Sixteen academic and nonacademic centers were 
contacted, of which 13 agreed to participate in this analysis. 
Reasons for refusal were, too small patient numbers (n = 
2) and lack of resources to complete follow-up (n = 1). All 
participating centers were located in Germany (n = 11) and 
Austria (n = 2), and all, except for one German center, were 
academic hospitals. Data of 642 patients were collected; 
60 patients were excluded because of cN+ or cM+ disease, 
resulting in 582 eligible patients.
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Figure 1 shows introduction of SBRT over time: two 
institutions started SBRT for stage I NSCLC in 1998, and all 
13 institutions practiced SBRT by the year 2008. In 2010, the 
last full year covered in this analysis, 95 patients in total were 
treated with SBRT. The median number of patients per institu-
tion was 39 (range, 8–110), and the median number of patients 
per institution and year was five (range, 1–29). Patient and 
treatment characteristics are summarized in Table 1.
Time trends in patient characteristics were analyzed 
and are summarized in Table 1. No time trend was observed 
for patient age, pretreatment performance status, pretreat-
ment pulmonary function, and maximum tumor diameter. 
Histopathological confirmation was frequent (84.5%) but 
decreased over time with biopsy rates of 89.3% and 77.6% in 
1998–2008 and 2009–2011, respectively (p = 0.0003). Use of 
FDG-PET for staging increased continuously over time: FDG-
PET staging was first performed in 2000, and was practiced in 
52% to 57% of the patients between 2003 and 2006, in 71% 
to 81% between 2007 and 2009, and in more than 90% of the 
patients from 2010 onward (p < 0.0001).
Patterns of SBRT practice changed substantially over 
time. The PTV-encompassing dose was increased continu-
ously and reached a plateau of 94 Gy±26 Gy BED on aver-
age in 2006 to 2011 (p < 0.0001) (Fig. 2).
Single-fraction radiosurgery was performed at five 
centers, but 89 of 106 radiosurgical treatments were per-
formed at two institutions. The PTV-encompassing dose 
was increased from 20.4 ± 2.0 Gy to 24.9 ± 2.9 Gy in the 
time intervals 1998–2003 and 2004–2011, respectively. 
Dose inhomogeneity remained constant at 80% (PTV-
encompassing dose/maximum PTV dose).
In fractionated SBRT, the average single-fraction 
dose and dose inhomogeneity remained rather constant, 
whereas, the number of treatment fractions increased over 
time. The most frequently used fractionation schemas were 
3 × 12.5 Gy prescribed to the 60% to 65% isodose line 
(n = 147) and 3 × 15 Gy prescribed to the 65% isodose line 
(n = 107). Only six patients were treated with more than 10 
fractions. All except three institutions used a minimum of 
two risk-adapted fractionation schemas with the number of 
fractions and single-fraction doses adjusted to tumor size 
and location.
A more accurate dose calculation algorithm (type B 
instead of type A)13 was used in 25% and 52% of the patients 
between 1998–2006 and 2007–2011, respectively (p < 0.0001). 
The method of patient setup and image guidance changed rap-
idly over time. SBRT with stereotactic patient setup (no image 
guidance for direct visualization of the pulmonary target) was 
practiced in 70 patients only: this was the most frequently 
practiced method until 2001 (56% of all treatments) and was 
last performed in 2009. Daily pre-SBRT CT resimulation out-
side the treatment room started in 1998 and was the predomi-
nant image-guided radiotherapy (IGRT) technology between 
2002 and 2006 (57% of all treatments). In-room IGRT started 
in 2002 and was the leading IGRT technology from 2007; 
daily pre-SBRT in-room image guidance was used in 92% of 
all treatments in 2011. Intrafractional patient-immobilization 
devices like the stereotactic bodyframe or customized vacuum 
cushions were used on all patients.
No significant interinstitutional variability was observed 
for patient age, pretreatment pulmonary function, and maxi-
mum tumor diameter but for pretreatment performance status, 
histopathological confirmation, and use of FDG-PET staging 
(all p < 0.01) (Table 1). SBRT practice varied significantly 
in terms of radiotherapy dose, fractionation, dose calculation 
algorithm, and IGRT technology (all p < 0.001).
Patterns-of-Outcome
Average follow-up for all patients was 21.4 months and 
the maximum was 144 months; follow-up was more than 3 
years for 108 patients. Three-year FFLP was 79.6% for all 582 
patients (Fig. 3); the pattern of disease recurrence was dis-
tant with 3-year freedom from distant metastasis and regional 
metastasis of 63.4% and 75.4%, respectively. Three-year OS 
was 47.1% (Fig. 4). Three patients (0.5%) died within 30 days 
after SBRT and 10 (1.7%) within 60 days
Results of Univariate Analyses for 
Factors Influencing FFLP and OS 
Table 2 shows that FFLP was most significantly influ-
enced by the PTV-encompassing dose in BED, dose inhomo-
geneity within the PTV, and technology for patient setup and 
IGRT (all p < 0.01). The cutoff dose of 106 Gy BED was cal-
culated in ROC analysis, and FFLP reached a plateau of 92.5% 
after SBRT with 106 Gy BED or more. In addition, tumor stage, 
histopathology, and number of SBRT procedures per year and 
institution affected FFLP significantly (all p < 0.05). A signifi-
cant dose–effect relationship regarding FFLP was observed for 
stage IA (p = 0.01) and stage IB (p = 0.05), resulting in identi-
cal 3-year FFLP of 92.6% and 92.2% for stage IA and stage 
IB, respectively, after irradiation with more than 106 Gy BED.
Most significant factors influencing OS were pretreatment 
performance status and PTV-encompassing dose in BED (all p 
< 0.001). Additional parameters affecting OS were tumor stage, 
dose calculation algorithm (all p < 0.01), pretreatment forced 
expiratory volume in 1 second, histopathology, and number 
of SBRT procedures per year and institution (all p < 0.05). 
FIGURE 1.  Patterns of implementation and practice of SBRT 
in 13 centers in Germany and Austria. SBRT, stereotactic body 
radiotherapy.
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Similar to FFLP, the irradiation dose significantly influenced 
OS in both stage IA (p = 0.01) and IB (p = 0.02). Whereas OS 
was significantly different between stage IA and stage IB in the 
low-dose cohort (3a OS 47.8% versus 34.8%; p = 0.03), this 
difference was not significant in the high-dose cohort (3a OS 
64% versus 58.3%; p = 0.25).
Results of the MVA are shown in Table 3. The most 
important factor influencing clinical outcome was the 
PTV-encompassing dose: irradiation doses of 106 Gy BED 
or more were associated with better OS (hazard ratio [HR] = 
0.62) and FFLP (HR = 0.39).
Grade of toxicity was not available for one institution 
and patients from that institution were excluded from toxic-
ity analysis. Radiation-induced pneumonitis grade 2 or higher 
was observed in 38 of 512 patients (7.4%) and grade 5 pneu-
monitis was documented in two patients (0.4%).
TABLE 1.  Patient and Treatment Characteristics with Analyses for Time Trends and Inter-Institutional Variability
No. of 
Patients % Median Minimum Maximum
Time 
Trend
Interinstitutional 
Variability
Age (yr) 582 72.2 30.9 92.4 0.07 NS
Sex 0.43 p < 0.001
 Male 405 69.6
 Female 177 30.4
Baseline Karnofsky Index 540 80 40 100 0.40 p <0.001
Baseline FEV
1
 (%) 446 58 16 129 0.97 0.50
Biopsy confirmation of NSCLC p < 0.001 p < 0.001
 No 90 15.5
 Yes 492 84.5
Clinical stage 0.01 p < 0.001
 IA 327 56.2
 IB 236 40.5
 I 19 3.3
Staging FDG-PET p < 0.001 p < 0.001
 No 142 24.4
 Yes 415 71.3
 Unknown 25 4.3
Histology 0.08 p < 0.001
 Adeno Ca 231 39.7
 SCC 195 33.5
 Other 55 9.5
 Unknown or no biopsy 101 1.9
Maximum tumor diameter (cm) 347 2.5 0.8 4.9 0.34 0.51
Dose calculation algorithm p < 0.001 p < 0.001
 Type A 265 45.5
 Type B 249 42.8
 Unknown 68 11.7
Number of SBRT fractions 582 3 1 20 0.02 p < 0.001
Single-fraction dose PTV- 
encompassing (Gy)
582 12.5 2.9 33.0 p < 0.001 p<0.001
Total dose PTV- 
encompassing (Gy)
582 37.5 12.0 64.0 p < 0.001 p < 0.001
Dose inhomogeneity (PTV- 
encompassing dose/ 
maximum PTV dose) (%)
582 65 60 100 p < 0.001 p < 0.001
Total BED PTV- 
encompassing (Gy)
582 84.4 38.3 180.0 p < 0.001 p < 0.001
Patient setup and IGRT p < 0.001 p < 0.001
 Stereotactic setup 70 12.0
 Resimulation outside 
teratment room
165 28.4
 In-room IGRT 347 59.6
FEV
1
, forced expiratory volume in 1 second; NSCLC, non–small-cell lung cancer; FDG-PET, fluoro-deoxy-glucose positron emission tomography; SCC, squamous cell carcinoma; 
Adeno Ca, adenocarcinoma; SBRT, stereotactic body radiotherapy; PTV, planning target volume; BED, biological effective dose; IGRT, image-guided radiotherapy.
1054 Copyright © 2013 by the International Association for the Study of Lung Cancer
Guckenberger et al. Journal of Thoracic Oncology ®  •  Volume 8, Number 8, August 2013
DISCUSSION
SBRT was introduced in Germany and Austria in 1998, 
a few years after this concept had been first described in Japan 
and Sweden.14,15 As a consequence, this represents one of the 
largest data sets, with 582 stage I NSCLC patients treated at 
13 centers between 1998 and 2011.
SBRT was safe in this multi-institutional environment: 
30- and 60-day mortality rates were low at 0.5% and 1.7%, 
respectively, and only two cases of grade 5 toxicity were 
observed. However, efficacy of SBRT seems worse in our 
analysis compared with that in published prospective phase 
II studies and large retrospective analyses: 3-year FFLP was 
79.6% and 3-year OS was 47.1%. However, the strongest 
predictor for FFLP and OS in univariate analysis and MVA 
was the PTV-encompassing irradiation dose, which has been 
continuously escalated with time and reached a plateau at 94 
Gy BED on average from 2006. After treatment with irradia-
tion doses of 106 Gy BED or more (patients n = 164; insti-
tutions n = 7) 3-year FFLP was 92.5% and 3-year OS was 
62.2%. Recurrence rates are now in good agreement with the 
published prospective trials and OS seems even favorable. A 
dose–effect relationship for local tumor control is well docu-
mented16–20 and has been described for OS by several stud-
ies.18,19,21,22 These results indicate that intensified SBRT with 
the consequence of improved local tumor control transfers 
into improved OS.
Substantially higher doses of three fractions of 18 to 
20 Gy (151–180 Gy BED) are usually used in SBRT based 
on the phase I study by McGarry et al.23 However, a recent 
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FIGURE 2.  Time trend of irradiation 
dose in stereotactic body radiotherapy. 
BED, biological effective dose; PTV, plan-
ning target volume. 
FIGURE 3.  Freedom from local progression for the total 
patient population. FIGURE 4.  Overall survival for the total patient population.
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TABLE 2.  Univariate Analysis of Factors Influencing OS and FFLP
OS FFLP
Cutoff No. of Patients p 3a OS p 3a FFLP
Age (yrs) 0.33 0.53
 <75 yr 358
 ≥75 yr 224
Sex 0.69 0.65
 Male 405
 Female 177
Performance status 0.0002 0.79
 <80 184 35.4
 ≥80 358 53.0
Pre-SBRT FEV
1
 (%) 0.03 0.29
 <58 222 43.2
 ≥58 224 55.7
Stage 0.003 0.048
 IA 327 53.1 84.0
 IB 236 40.0 74.3
Histopathology 0.05 0.02
 No biopsy 99 27.4 64.4
 SCC 195 44 75.3
 Adeno Ca 231 56.3 86.5
 Other 55 50.3 92.5
Staging FDG-PET 0.09 0.056
 Yes 415
 No 142
PTV-encompassing dose (Gy BED) 0.0001 0.001
 <106 418 42.4 74.1
 ≥106 164 62.1 92.1
Dose inhomogeneity (PTV-encompassing dose/ 
maximum dose) (%)
0.87 0.005
 <80 377 86.8
 ≥80 205 69.1
Dose calculation algorithm 0.002 0.19
 Type A 46.0
 Type B 51.3
Patient setup 0.20 0.006
 Stereotactic 70 66.7
 IGRT outside 165 77
 IGRT inside 347 83.1
SBRT procedures / institution 0.13 0.056
 <22 247
 ≥22 335
SBRT procedures / year and institution 0.03 0.01
 <9 341 44.1 73.9
 ≥9 241 51.2 87.7
Three-year (3a) OS and FFLP is only shown for significant differences.
OS, overall survival; FFLP, freedom from local progression; SBRT, stereotactic body radiotherapy; BED, biological effective dose; PTV, planning target volume; FDG, ; PET, 
positron emission tomography; IGRT, image-guided radiotherapy; SCC, squamous cell carcinoma; Adeno.Ca, adenocarcinoma.
meta-analysis suggested the best therapeutic ratio for SBRT 
at intermediate doses between 83.2 and 146 Gy BED: OS was 
significantly decreased after SBRT with doses more than 146 
Gy BED, indicating occult toxicity. Doses more than 146 Gy 
BED were used in only 2.7% of our patients (n = 16) and the 
low 3-year OS of 47% confirms the hypothesis by Zhang et al.22
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The strong dose–effect relationship observed in our 
study maybe surprising considering the large range of sin-
gle-fraction doses up to 33 Gy, where applicability of the 
linear-quadratic model is uncertain. In addition, the analyzed 
PTV-encompassing doses may or may not be representative of 
the true tumor dose, considering the variability in the target vol-
ume and safety margin concepts, dose calculation algorithms, 
and differences in IGRT practice. However, another interpreta-
tion could be that all these uncertainties are of smaller clini-
cal relevance than previously estimated. The irradiation dose 
was significantly correlated with all outcome parameters in the 
MVA, where all available confounding factors like tumor stage, 
use of advanced technologies, and experience in SBRT were 
included. This conclusion is supported by the close agreement 
of our results with a recent multicenter analysis, where the pla-
teau of the dose–effect relationship for local tumor control was 
found at 105 Gy BED,24 which is identical to our results.
A recent national patterns-of-care analysis in the United 
States described large interinstitutional variability in the 
practice of lung SBRT.25 In our study, we observed a simi-
lar interinstitutional variability and, furthermore, substantial 
time trends of SBRT planning and delivery, which occurred 
in parallel to introduction of SBRT. Centers in our study were 
among the pioneers evaluating advanced technologies like 
FDG-PET staging,26 advanced dose calculation algorithms,27 
and volumetric in-room IGRT28 for lung SBRT. As a conse-
quence of their rapid adoption, these technologies became the 
standard of care from 2003 to 2008, with application in more 
than 50% of the patients and centers. In 2010 and 2011, these 
three technologies were routine practice in 11 of 13 centers.
It was interesting that the introduction of these mod-
ern technologies did not significantly improve any outcome 
parameter: staging using FDG-PET, image guidance instead of 
stereotactic patient setup, and more accurate type B dose cal-
culation algorithms did not influence OS or recurrence patterns 
(local, regional, and distant failures; detailed data not shown). 
However, the introduction of these more accurate radiotherapy 
technologies was accompanied by a parallel escalation of the 
irradiation dose. This intensification of SBRT was not asso-
ciated with increased rates of radiation-induced pneumonitis: 
the rates of pneumonitis grade 2 or more were 6.8% and 7.6% 
in the time periods 1998–2005 (low-dose period) and 2006–
2011 (high-dose period), respectively. This indicates that more 
precise SBRT planning and delivery compensated the poten-
tially more toxic effect of substantially increased irradiation 
doses. A detailed analysis of toxicity remains to be performed. 
Furthermore, advanced technologies have streamlined the 
SBRT work-flow and increased the confidence into the treat-
ment accuracy and might therefore have contributed to the 
rapid adoption of SBRT in the radiotherapy community.
The institution where SBRT was performed and insti-
tutional-specific experience in SBRT with total number of 
SBRT procedures and number of SBRT procedures per year 
were not significantly correlated with OS or recurrence rates. 
In addition, no learning curve based on the number of patients 
treated after the introduction of SBRT in each institution was 
observed. These results indicate that SBRT outside of homo-
geneous study protocols is safe and effective despite details 
in SBRT practice, which varied substantially between the 
institutions.
However, this needs to be interpreted in the specific 
context of our analysis. The working group Extracranial 
Stereotactic Radiotherapy of the German Society for Radiation 
Oncology was established in 2004, and this group has orga-
nized annual teaching courses about SBRT. National guide-
lines with detailed recommendations about all major clinical, 
technical, and quality-assurance aspects of SBRT have been 
published in 2006. Consequently, results of this analysis were 
achieved in an academic environment, and implementation 
of SBRT was guided by multiprofessional support of a dedi-
cated working group. Similar guidelines have been published 
recently on a national and international level.13,29–32 Although 
TABLE 3.  Multivariate Analysis of Factors Influencing OS and FFLP
OS FFLP
Parameter p HR 95% CI p HR 95% CI
Performance status <80 0.02 1.44 1.05 to 1.97
Clinical stage IB 0.007 1.52 1.12 to 2.07 0.08 1.66 0.95 to 2.92
Baseline FEV
1
 (%) Continuous 
variable
0.07 0.99 0.99 to 1.00
Biopsy status No biopsy 0.09 1.49 0.94 to 2.35 0.02 2.53 1.17 to 5.48
Staging FDG-PET Yes >0.1
Histology SCC 0.03 2.03 1.06 to 3.89
PTV-encompassing dose  
(Gy BED)
≥106 0.01 0.62 0.43 to 0.90 0.04 0.39 0.16 to 0.93
Dose inhomogeneity  
(PTV-encompassing  
dose / maximum dose) (%)
≥ 80 0.06 1.74 0.98 to 3.08
IGRT technology In-room IGRT >0.1
SBRT procedures/institution and year <9 >0.1 >0.1
OS, overall survival; CI, confidence interval; FFLP, freedom from local progression; HR, hazard ratio; FEV
1
, forced expiratory volume in 1 second; SCC, spindle cell carcinoma; 
SBRT, stereotactic body radiotherapy; BED, biological effective dose; FDG-PET, fluoro-deoxy-glucose positron emission tomography; IGRT, image-guided radiotherapy; PTV, 
planning target volume.
1057Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 8, August 2013 Patterns-of-Care Analysis of SBRT for Stage I NSCLC
not all technical details are defined in these guidelines, adher-
ence to such recommendations, participation in structured 
teaching events, and strict quality-assurance protocols are 
considered as essential for safe implementation of modern 
and complex technologies.
In contrast to the time trends in SBRT practice and 
interinstitutional variability in the methods of SBRT, there 
was no significant interinstitutional variability in patient age 
and pulmonary function, which is the dominant reason for 
being medically inoperable and being treated with SBRT. This 
indicates that the indication for SBRT was rather uniform in 
Germany and Austria. Our data further suggest that the indi-
cation for SBRT in Germany and Austria has not changed 
systematically over time: no time trend in the patient char-
acteristics to younger age, better pretreatment performance 
status, and better pulmonary function was observed.
Some limitations of our analysis need to be discussed, 
most are inherent to retrospective multicenter analyses. The 
number of variables was limited such that not all aspects of 
SBRT and all potential factors influencing outcome were 
available. Definition of local tumor progression is challenging 
in SBRT, with many patients developing fibrosis in the treated 
volume.33 We did not have a central review of all local recur-
rences but FFLP was taken as reported by the specific insti-
tution. In addition, it is highly likely that definition of local 
progression changed in the 14-year period of this analysis: 
FDG-PET for staging became available in 2000 and was prac-
ticed in more than 50% of the patients from 2003: a similar 
time trend for FDG-PET–based differentiation of fibrosis and 
local progression is expected.
Strengths of our analysis are the comprehensive cover-
age of the patterns of SBRT practice and outcome in Germany 
and Austria from the very beginning of SBRT introduction 
in 1998; potential SBRT practice in private practice outside 
of academic centers was not analyzed. The large number of 
patients, sufficiently long follow-up, and especially, the vari-
ability in important aspects of SBRT practice allowed mod-
eling and analysis of factors influencing outcome of SBRT, 
which is not possible in standardized prospective trials.
CONCLUSIONS
SBRT for stage I NSCLC was safe and effective in 
this multi-institutional environment and treatment outside of 
prospective clinical trials. Despite variability in the details 
of SBRT practice, consistent results were observed without 
evidence of a learning curve or improvement of results with 
larger SBRT experience and implementation of new radio-
therapy technologies. However, strict quality assurance and 
structured implementation within an academic environment 
and assistance of a dedicated working group of the national 
radiotherapy society were the basis for our results. In addition, 
radiotherapy dose was identified as a major treatment factor 
influencing local tumor control and OS.
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